Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults

Clinical Infectious Diseases

Volumn 33, Issue 11, 2001, Pages 1879-1885

  Muennig, Peter A ^a   Khan, Kamran ^b  

^a NEW SCHOOL FOR SOCIAL RESEARCH   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; OSELTAMIVIR; SIALIDASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GEOGRAPHIC DISTRIBUTION; HOSPITALIZATION; HUMAN; INFLUENZA; MALE; PATIENT CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; VACCINATION; VIRUS INACTIVATION; VIRUS INFECTION;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; ENZYME INHIBITORS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; NEURAMINIDASE; OSELTAMIVIR; VACCINES, INACTIVATED;

EID: 0035576917     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/324491     Document Type: Article

References (39)

1. Impact of epidemic type A influenza in a defined adult population
2. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981
3. The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community
4. Influenza-associated morbidity and mortality in young and middle-aged women
5. The effectiveness of vaccination against influenza in healthy, working adults
6. Clinical effectiveness and cost effectiveness of influenza vaccination among healthy working adults
7. Influenza vaccination, cost-effectiveness and public policy
8. Cost-effectiveness of the influenza vaccine in a healthy, working-age population
9. Effectiveness and cost-benefit of influenza vaccination of healthy working adults
10. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections
11. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza
12. Zanamivir in the prevention of influenza among healthy adults
13. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza
14. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
15. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza epidemics
16. Neuraminidase inhibitors for treatment of influenza A and B infections
17. Effectiveness of influenza vaccine in health care professionals
18. Incidence, utilization, and costs associated with acute respiratory conditions
19. A pharmacoeconomic model for the treatment of influenza
20. The economic impact of pandemic influenza in the United States: Priorities for intervention
21. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population
22. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78
23. A general health policy model: Update and applications
24. Toward consistency in cost-utility analyses: Using national measures to create condition-specific values
25. Applications of multi-attribute utility theory to measure social preferences for health states
26. Influenza: Virology, epidemiology, disease, and prevention
27. The cost-effectiveness of strategies for the treatment of intestinal parasites in immigrants
28. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people
29. Prevention Neuraminidase inhibitors for treatment of influenza A and B infections
30. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomized, double-blind, placebo-controlled European study